Travere Therapeutics, Inc.
TVTX
Clasificación en acciones
#3481
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Precio por acción
$52.43
Capitalización bursátil
$4.94B
Cambio (1 día)
3.83%
Cambio (1 año)
87.97%
País
US
Comercio Travere Therapeutics, Inc. (TVTX)
Categoría
Healthcare
Número de acciones en circulación de Travere Therapeutics, Inc. (TVTX)
Número de acciones en circulación al June 2026: 93.48M
Según los últimos informes financieros y el precio de las acciones de Travere Therapeutics, Inc., el número actual de acciones en circulación es 93.48M. Al final de December 2023, la empresa tenía 74.27M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Travere Therapeutics, Inc. (TVTX) desde 2009 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 93.48M | 18.49% |
| 2024 | 78.89M | 6.22% |
| 2023 | 74.27M | 16.48% |
| 2022 | 63.76M | 6.56% |
| 2021 | 59.83M | 25.86% |
| 2020 | 47.54M | 12.28% |
| 2019 | 42.34M | 4.74% |
| 2018 | 40.42M | 4.27% |
| 2017 | 38.77M | 4.79% |
| 2016 | 37.00M | 10.24% |
| 2015 | 33.56M | 34.01% |
| 2014 | 25.04M | 76.47% |
| 2013 | 14.19M | 13,200.13% |
| 2012 | 106.70K | -99.89% |
| 2009 | 95.91M | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| 253.90M | 171.61% |
US
|
|
| 396.00M | 323.62% |
US
|
|
| 478.91M | 412.32% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -33.48% |
NL
|
